Multiple SclerosisNCT07411924
Mastication, Cognition, and Nutritional Status in Multiple Sclerosis
An observational study of Multiple Sclerosis, run by Ondokuz Mayıs University.
Trial summary
The aim of this study is to investigate the relationship between chewing function and cognitive functions, disease severity, and nutritional status in individuals diagnosed with Multiple Sclerosis Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 86 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 1 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of individuals aged 18 years and older diagnosed with Multiple Sclerosis who are followed up at the neurology outpatient clinics.
Who may be able to join
- Being 18 years of age or older
Who cannot join
- Having a neurological or systemic disease other than Multiple Sclerosis that may affect chewing function
- Inability to provide adequate communication or cooperation due to psychiatric disorders
- Not being diagnosed with Multiple Sclerosis
- Not volunteering to participate in the study
- Presence of severe problems preventing questionnaire administration (visual and/or hearing impairments)
- History or presence of psychiatric and/or other neurological disorders
Show all 12Show fewer
- Presence of severe neurological findings that may negatively affect cognitive performance (e.g., severe optic neuritis)
- Use of medications affecting cognitive functions
- Alcohol or substance use
- Having experienced a relapse within the last month
- Having received corticosteroid treatment within the last month
- History of stroke, head and neck cancer, or rheumatic diseases that may affect swallowing and chewing performance
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Investigation of the Relationship Between Chewing Function and Cognitive Functions, Disease Severity, and Nutritional Status in Individuals With Multiple Sclerosis
The aim of this study is to investigate the relationship between chewing function and cognitive functions, disease severity, and nutritional status in individuals diagnosed with Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Multiple Sclerosis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expanded Disability Status Scale (EDSS)
Measured: Baseline
Montreal Cognitive Assessment (MoCA)
Measured: Baseline
Turkish version of the Eating Assessment Scale (T-EAT-10)
Measured: Baseline
Dysphagia in Multiple Sclerosis (DYMUS)
Measured: Baseline
Test of Masticating and Swallowing Solids (TOMASS)
Measured: Baseline
Mini Nutritional Assessment Short Form (MNA)
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ondokuz Mayıs University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seda Nur Kemer, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07411924
- Sponsor's protocol ID
- 2025/283
- Status last verified
- Jul 2025
- First submitted
- 9 Feb 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Relationship Between Chewing Function and Cognitive Functions, Disease Severity, and Nutritional Status in Individuals With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07411924
- Acronym / sponsor ID
- 2025/283
- Conditions
- Multiple Sclerosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Ondokuz Mayıs UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate the relationship between chewing function and cognitive functions, disease severity, and nutritional status in individuals diagnosed with Multiple Sclerosis
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multiple Sclerosis | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of individuals aged 18 years and older diagnosed with Multiple Sclerosis who are followed up at the neurology outpatient clinics.
Key inclusion criteria (1 listed)
- Being 18 years of age or older
Key exclusion criteria (12 listed)
- Having a neurological or systemic disease other than Multiple Sclerosis that may affect chewing function
- Inability to provide adequate communication or cooperation due to psychiatric disorders
- Not being diagnosed with Multiple Sclerosis
- Not volunteering to participate in the study
- Presence of severe problems preventing questionnaire administration (visual and/or hearing impairments)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Expanded Disability Status Scale (EDSS)
Time frame: Baseline
Montreal Cognitive Assessment (MoCA)
Time frame: Baseline
Turkish version of the Eating Assessment Scale (T-EAT-10)
Time frame: Baseline
Dysphagia in Multiple Sclerosis (DYMUS)
Time frame: Baseline
Test of Masticating and Swallowing Solids (TOMASS)
Time frame: Baseline
Mini Nutritional Assessment Short Form (MNA)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
Active, not recruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
RecruitingObservational study
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Ondokuz Mayıs University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seda Nur Kemer, PhD (+905467861866, sedakemer@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Expanded Disability Status Scale (EDSS) (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.